Avidity Biosciences Reports First Quarter 2022 Financial Results and Recent Highlights

/PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody...

Related Keywords

San Diego ,California ,United States ,Ukraine ,American ,Michael Maclean ,Cherise Adkins ,Steve Hughes ,Kathleen Gallagher ,Mike Maclean ,Eli Lilly ,Sarah Boyce ,Linkedin ,Twitter ,Company Contact ,Prnewswire Avidity Biosciences Inc ,Nasdaq ,Exchange Commission ,Development Rd Expenses ,American Academy Of Neurology ,Avidity Biosciences Inc ,Antibody Oligonucleotide Conjugates ,American Academy ,Cash Equivalents ,Marketable Securities ,Oligonucleotide Conjugates ,Private Securities Litigation Reform Act ,Months Ended March ,Avidity Biosciences ,Nc ,